The American Journal of Managed Care

Primary Sclerosing Cholangitis Treatment Varies Significantly Among Care Centers

The survey of European hepatologists demonstrates the lack of clarity in guidelines. A new survey of European health care centers with expertise in managing primary sclerosing cholangitis (PSC) ...
MarketWatch

Primary Sclerosing Cholangitis Market Outlook Highlights Rising Demand and Expanding Treatment Landscape Throughout the Forecast Period (2025-2034) | DelveInsight

According to DelveInsight's analysis, the primary sclerosing cholangitis market is anticipated to grow during the forecast period (2025--2034), driven by the launch of emerging therapies such as LB-P8 ...
Seeking Alpha

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis

PARIS, FRANCE, 10 June 2024 Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Iqirvo ® (elafibranor) 80 mg tablets ...
Seeking Alpha

Ipsen’s Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decade

European Commission grants conditional marketing authorization for Iqirvo ® (elafibranor), first-in-class new treatment for primary biliary cholangitis (PBC), a rare liver disease Approval follows ...
PR Newswire

Primary Sclerosing Cholangitis Market to Grow at a Tremendous CAGR of 17.2% During the Study Period (2019-2032) | DelveInsight

The overall market of primary sclerosing cholangitis (PSC) is expected to boost due to the expected launch of emerging therapy in the forecasted period (2023–2032). Primary sclerosing cholangitis (PSC ...
ascopubs.org

Incidence and risk factors for cholangitis during systemic chemotherapy among patients with advanced biliary tract cancer.

In vitro sensitivity to 5-FU and gemcitabine in pancreatic cancer. Background: Patients with biliary tract cancer (BTC) have a high risk of developing cholangitis. In patients with advanced BTC ...
Medindia

Primary Sclerosing Cholangitis Market Outlook Highlights Rising Demand and Expanding Treatment Landscape Throughout the Forecast Period (2025-2034) | DelveInsight

Primary Sclerosing Cholangitis Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, ...
Mena FN

Primary Sclerosing Cholangitis Market Outlook Highlights Rising Demand And Expanding Treatment Landscape Throughout The Forecast Period (2025-2034) Delveinsight

Inflammatory Bowel Disease Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the ...